The U.S. Food and Drug Administration (FDA) has approved Actoplus Met® (pioglitazone and metformin) for the treatment of type 2 diabetes in adults. It comes in the form of a tablet, and is taken either once or twice a day, as your healthcare provider recommends.
This combination drug works in a few different ways. The first active ingredient -- pioglitazone -- works by improving the body's sensitivity to insulin. The other component of Actoplus Met -- metformin -- reduces the amount of sugar the body produces, as well as how much it removes from food. When these effects are combined, the result is lowered blood sugar.
Due to the metformin, Actoplus Met can cause a rare but potentially serious side effect known as lactic acidosis. Possible signs include muscle pain, stomach pain, trouble breathing, and chest pain. If you experience these or any other problems while taking this drug, contact your healthcare provider right away.
(Click Actoplus Met to learn more about this diabetes drug, including other effects on the body, additional side effects to be aware of, what to discuss with the healthcare provider prescribing it, and more.)
Written by/reviewed by: Kristi Monson, PharmD;Arthur Schoenstadt, MD
Food and Drug Administration, Center for Drug Evaluation and Research. Electronic orange book: approved drug products with therapeutic equivalence evaluations. FDA Web site. Available at: http://www.fda.gov/cder/ob/. Accessed January 18, 2007.
Mylan, Inc. Mylan announces first-to-file opportunity settlement agreements for Actoplus Met(R) and Actos(R) (3/16/2010). Mylan Web site. Available at: http://investor.mylan.com/releasedetail.cfm?ReleaseID=452248. Accessed April 1, 2010.
eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind.
Site users seeking medical advice about their specific situation should consult with their own physician. Click